Influenza Vaccine, mRNA
| Brand name | flusiva,mflusiva |
|---|---|
| Active ingredient | Influenza Vaccine, mRNA |
| Strength | 37.5UG |
| Dosage form | For Injection |
| Route | Intramuscular |
| Modality | Biologic |
| FDA approval | August 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.